mocertatug rezetecan

News

GSK's B7-H4-targeting ADC Mo-Rez chalks up impressive results in ovarian and endometrial cancer, prompting a major phase 3 trials programme.

News

Cytokinetics' Myqorzo has succeeded where BMS's first-to-market Camzyos failed, with a positive trial in non-obstructive hypertrophic cardiomyopathy.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.